David Einhorn, Founder and President of Greenlight Capital exited his stakes in Intel (INTC), Rivian Automotive (RIVN), and News Corp.
Keep Reading →
February 15 - Hedge Funds, Insider Trading - Comments
In this article, we will take a look at the 15 best dividend stocks right now.
Keep Reading →
April 8 - Hedge Funds, News - Comments
Anyone looking to learn how a quant fund conquered the financial world should go out and buy Greg Zuckerman’s “The Man Who Solved the Market” when it’s released next week...
Keep Reading →
November 1 - Hedge Funds, Insider Trading - Comments
Ray Dalio, the billionaire founder of the world’s largest hedge fund, said there’s about a 25% chance of a U.S.
Keep Reading →
September 5 - Hedge Funds, Insider Trading - Comments
Quantitative funds are gaining more ground among hedge funds in terms of trading volume and inflow of capital.
Keep Reading →
December 28 - Hedge Funds, News, Quantitative Investing - Comments
If you're seeking to invest in stocks with great long-term potential and are interested in adding some exposure to the healthcare sector, then the 15 biggest healthcare companies...
Keep Reading →
July 6 - News - Comments
How To Become A Successful Investor? Being a successful investor is difficult. The market can be very random and completely irrational much of the time.
Keep Reading →
March 26 - Lists, News - Comments
At the end of last week, Amgen, Inc. (NASDAQ:AMGN) announced some data from its large-scale trial of its cardiovascular risk asset Repatha.
Keep Reading →
March 20 - News, Stock Analysis - Comments
Although all three major indexes have rebounded into the green this afternoon, shares of five companies, Amgen, Inc.
Keep Reading →
March 17 - Market Movers, News - Comments
As a healthcare-focused fund, Michael Castor's Sio Capital registered a terrible 2016, as it lost 18.7% net, compared to the 12% gain registered by the S&P 500 and the 8.3% drop...
Keep Reading →
March 3 - Hedge Fund Investor Letters, Hedge Funds, News - Comments
A few weeks ago, President Donald Trump met with a series of biotech CEOs to discuss a historically major pain point for the industry: cutting the FDA drug approval process "at...
Keep Reading →
February 23 - News, Stock Analysis - Comments
Correction: A previous version of this article erroneously presented older events about the case between Sanofi/Regeneron and Amgen.
Keep Reading →
February 9 - News, Stock Analysis - Comments
Etelcalcetide, an Amgen, Inc. (NASDAQ:AMGN) drug that is meant to treat secondary hyperparathyroidism has been approved by the U.S. Food and Drug Administration.
Keep Reading →
February 8 - News, Stock Analysis - Comments
Esperion Therapeutics Inc (NASDAQ:ESPR) picked up strength at the end of last week, on the back of some news that – at first glance – seems unrelated to its own operations...
Keep Reading →
February 7 - News, Stock Analysis - Comments
What does 2017 hold for Amgen, Inc.
Keep Reading →
January 23 - News, Stock Analysis - Comments
After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead Sciences, Inc.
Keep Reading →
December 23 - News, Stock Analysis - Comments
"Despite being one of the few prominent investors in the world to recognize the bubble brewing in the subprime mortgage markets and the crisis it would lead to when it burst, ...
Keep Reading →
November 30 - Hedge Funds - Comments
Third Avenue Management is a New York-based investment fund that uses a deep value investing strategy for stock selection.
Keep Reading →
October 29 - Hedge Fund Investor Letters, Hedge Funds, News - Comments
All three indexes are in the green today after U.S. consumer confidence jumped to its highest figure in nine years during September.
Keep Reading →
September 27 - Market Movers, News - Comments
Romosozumab (AKA romo) from Amgen Inc (NASDAQ:AMGN) and Belgium-based UCB, which is in its Phase III FRAME study is yet to achieve any regulatory approval from the FDA until ...
Keep Reading →
September 20 - News, Stock Analysis - Comments
Coherus Biosciences Inc (NASDAQ:CHRS) submitted a biologics licensing application (BLA) for its lead biosimilar development candidate earlier this month, and is drawing a lot ...
Keep Reading →
August 16 - News, Stock Analysis - Comments
Given that it's the middle of earnings season, it's not surprising that many major companies are trending today.
Keep Reading →
July 28 - Earnings Report, News - Comments
The biosimilar space is relatively young.
Keep Reading →
July 12 - News, Stock Analysis - Comments
Paul Holland and Matthew Miller co-founded Glaxis Capital in 2005. The fund's equity portfolio has remained fairly concentrated since the end of March last year.
Keep Reading →
May 16 - Hedge Funds, News, Tech - Comments
The ten S&P 500 companies that have increased their dividend payout by the highest average annual rate during the last five years are analyzed in this article.
Keep Reading →
May 6 - Dividend Stocks, News, Stock Analysis - Comments
There are various reasons why corporate insiders might sell shares of their own companies.
Keep Reading →
May 4 - Dividend Stocks, Insider Trading, News - Comments
Billionaire Daniel S. Loeb founded activist hedge fund Third Point LLC in 1995.
Keep Reading →
April 24 - Dividend Stocks, Hedge Fund Analysis, Hedge Funds, News - Comments
Biotech has undoubtedly been one of the most cherished industries, among hedge funds over the last few years and it's not hard to understand why.
Keep Reading →
December 20 - Hedge Funds, News - Comments
With crude futures failing to rally past a key technical resistance level, shares of Sunedison Inc (NYSE:SUNE), SolarCity Corp (NASDAQ:SCTY),Solaredge Technologies Inc (NASDAQ...
Keep Reading →
December 16 - Market Movers, News - Comments
Billionaire activist investor Dan Loeb of Third Point saw his hedge fund post losses of 8.9% for the September quarter in comparison to the S&P 500's slide of 6.4% during the ...
Keep Reading →
November 19 - Hedge Fund Analysis, Hedge Funds, News - Comments
Billionaire investor Dan Loeb, the founder of activist hedge fund Third Point LLC, discussed the performance of his investment firm, including the broader market conditions ...
Keep Reading →
November 16 - Hedge Fund Analysis, Hedge Funds, Macroeconomic Predictions, News - Comments
Sivik Global Healthcare is a Greenwich, Connecticut-based healthcare-focused hedge fund founded by Krishen Sud in 2006.
Keep Reading →
November 9 - Hedge Fund Analysis, Hedge Funds, News - Comments
When it comes to activist investing, Dan Loeb is one of the best in the business, generating strong returns through pushing companies to implement changes that maximize shareholder...
Keep Reading →
November 3 - Hedge Funds, News, Tech - Comments
When it rains, it pours, and for big pharma, it certainly poured in the third quarter.
Keep Reading →
October 20 - Hedge Funds, News - Comments
One of the best ways to pick high-performing stocks is to follow the industry leaders and find out their stock investments.
Keep Reading →
June 25 - Hedge Funds, News - Comments
Famous billionaire activist hedge-fund manager Dan Loeb of Third Point is renowned for the bombshells that he drops on the management of his target companies in the form of letters...
Keep Reading →
May 21 - Hedge Funds, News - Comments
March Altus Capital Management, headquartered in Greenwich, Connecticut, was founded by Neil Shah in December 2011.This healthcare focused fund follows bottom-up fundamental analysis...
Keep Reading →
April 16 - Hedge Funds, News - Comments
Headquartered in Connecticut, Sarissa Capital Management was founded by Alexander J. Denner in 2012. Prior to this, Mr.
Keep Reading →
April 15 - Hedge Funds, News - Comments
Considering that the second-largest holding of Dan Loeb's Third Point, Alibaba Group Holding Ltd (NYSE:BABA), lost 19.92% of its stock value during the first quarter, the fund...
Keep Reading →
April 8 - Hedge Funds, News - Comments
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Keep Reading →
March 26 - Hedge Funds, News - Comments
With the high volatility prevalent in the biotechnology sector, investors have a hard time picking the right stocks to invest in.
Keep Reading →
February 23 - Hedge Funds, News - Comments
Alex Denner’s Sarissa Capital Management recently disclosed its stock picks for the fourth quarter of 2014 in a 13F Form filed with the U.S.
Keep Reading →
February 21 - Hedge Funds, News - Comments
Dan Loeb`s Third Point filed its latest 13F with the SEC last week, detailing its long positions at the end of a self-admittedly poor year for the fund.
Keep Reading →
February 15 - Hedge Funds, News - Comments
Benjamin A. Smith’s Laurion Capital Management recently filed its 13F Form for last quarter with the U.S. Securities and Exchange Commission.
Keep Reading →
February 11 - Hedge Funds, News - Comments
The days of having no fund activity in Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) are over.
Keep Reading →
February 9 - Hedge Funds, News - Comments
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has, once again, shown today why biopharmaceuticals companies are so popular with investors, especially those with a speculative...
Keep Reading →
October 17 - News - Comments
Shares of Amgen, Inc.
Keep Reading →
August 14 - News - Comments
Amgen, Inc. (NASDAQ:AMGN) announced its second quarter financial results on July 29, 2014. Amgen's total revenues increased by 11% on the year to $5.18 billion.
Keep Reading →
July 30 - Earnings Report, News - Comments
Commenting on the market movements, CNBC reporter Bob Pisani gave a brief on the latest trends in the market and the sectors which are on a high in the ‘Squawk on the Street...
Keep Reading →
June 23 - Market Movers, News - Comments
